{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:55:45Z","timestamp":1791640545387,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01245-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:20:45Z","timestamp":1764840045000},"page":"467-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A 12-Week, Open-Label, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Lemborexant in Patients with Insomnia Comorbid with Depressive Episodes (SELENADE)"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-3249","authenticated-orcid":false,"given":"Yoshikazu","family":"Takaesu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-5341","authenticated-orcid":false,"given":"Hiroyuki","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-7524","authenticated-orcid":false,"given":"Masahiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-7272","authenticated-orcid":false,"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-5807","authenticated-orcid":false,"given":"Hirofumi","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-3054","authenticated-orcid":false,"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-4588","authenticated-orcid":false,"given":"Ken","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-7946","authenticated-orcid":false,"given":"Hitoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-3629","authenticated-orcid":false,"given":"Motohiro","family":"Ozone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-092X","authenticated-orcid":false,"given":"Yosuke","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Murao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-4304","authenticated-orcid":false,"given":"Takeshi","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-7070","authenticated-orcid":false,"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-3409","authenticated-orcid":false,"given":"Michinori","family":"Koebisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7836-611X","authenticated-orcid":false,"given":"Yuka","family":"Kawatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-4033","authenticated-orcid":false,"given":"Yoshiteru","family":"Takekita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"6","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1017\/s1092852900029266","volume":"15","author":"P Sunderajan","year":"2010","unstructured":"Sunderajan P, Gaynes BN, Wisniewski SR, Miyahara S, Fava M, Akingbala F, et al. Insomnia in patients with depression: a STAR*D report. CNS Spectr. 2010;15(6):394\u2013404. https:\/\/doi.org\/10.1017\/s1092852900029266.","journal-title":"CNS Spectr"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2015.11.025","volume":"191","author":"MK Steinan","year":"2016","unstructured":"Steinan MK, Morken G, Lagerberg TV, Melle I, Andreassen OA, Vaaler AE, et al. Delayed sleep phase: an important circadian subtype of sleep disturbance in bipolar disorders. J Affect Disord. 2016;191:156\u201363. https:\/\/doi.org\/10.1016\/j.jad.2015.11.025.","journal-title":"J Affect Disord"},{"issue":"12","key":"1245_CR3","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1176\/appi.ajp.2008.07121882","volume":"165","author":"HJ Cho","year":"2008","unstructured":"Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165(12):1543\u201350. https:\/\/doi.org\/10.1176\/appi.ajp.2008.07121882.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"1245_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","volume":"135","author":"C Baglioni","year":"2011","unstructured":"Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1\u20133):10\u20139. https:\/\/doi.org\/10.1016\/j.jad.2011.01.011.","journal-title":"J Affect Disord"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.smrv.2018.10.006","volume":"43","author":"E Hertenstein","year":"2019","unstructured":"Hertenstein E, Feige B, Gmeiner T, Kienzler C, Spiegelhalder K, Johann A, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev. 2019;43:96\u2013105. https:\/\/doi.org\/10.1016\/j.smrv.2018.10.006.","journal-title":"Sleep Med Rev"},{"issue":"8","key":"1245_CR6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.5665\/sleep.2008","volume":"35","author":"SX Li","year":"2012","unstructured":"Li SX, Lam SP, Chan JW, Yu MW, Wing YK. Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study. Sleep. 2012;35(8):1153\u201361. https:\/\/doi.org\/10.5665\/sleep.2008.","journal-title":"Sleep"},{"issue":"8","key":"1245_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1177\/0269881111421973","volume":"26","author":"LG Sylvia","year":"2012","unstructured":"Sylvia LG, Dupuy JM, Ostacher MJ, Cowperthwait CM, Hay AC, Sachs GS, et al. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol. 2012;26(8):1108\u201312. https:\/\/doi.org\/10.1177\/0269881111421973.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"1245_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.biopsych.2006.01.016","volume":"59","author":"M Fava","year":"2006","unstructured":"Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052\u201360. https:\/\/doi.org\/10.1016\/j.biopsych.2006.01.016.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"1245_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.4088\/JCP.09m05571gry","volume":"72","author":"M Fava","year":"2011","unstructured":"Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011;72(7):914\u201328. https:\/\/doi.org\/10.4088\/JCP.09m05571gry.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1245_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5664\/jcsm.27872","volume":"6","author":"WV McCall","year":"2010","unstructured":"McCall WV, Blocker JN, D\u2019Agostino R Jr, Kimball J, Boggs N, Lasater B, et al. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med. 2010;6(4):322\u20139.","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"1245_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/pcn.13811","volume":"79","author":"T Maruki","year":"2025","unstructured":"Maruki T, Takeshima M, Yoshizawa K, Maeda Y, Otsuka N, Aoki, et al. Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: a systematic review and meta-analysis of double-blind randomized controlled trials. Psychiatry Clin Neurosci. 2025;79(6):306\u201318. https:\/\/doi.org\/10.1111\/pcn.13811.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"1245_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-022-00974-6","volume":"37","author":"H Fagan","year":"2023","unstructured":"Fagan H, Jones E, Baldwin DS. Orexin receptor antagonists in the treatment of depression: a leading article summarising pre-clinical and clinical studies. CNS Drugs. 2023;37(1):1\u201312. https:\/\/doi.org\/10.1007\/s40263-022-00974-6.","journal-title":"CNS Drugs"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neubiorev.2020.07.040","volume":"118","author":"S Khairuddin","year":"2020","unstructured":"Khairuddin S, Aquili L, Heng BC, Hoo TLC, Wong KH, Lim LW. Dysregulation of the orexinergic system: a potential neuropeptide target in depression. Neurosci Biobehav Rev. 2020;118:384\u201396. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.07.040.","journal-title":"Neurosci Biobehav Rev"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euroneuro.2025.03.007","volume":"95","author":"ME Schmidt","year":"2025","unstructured":"Schmidt ME, Moyer JA, Kezic I, Zhou X, Samtani MN, Bleys C, et al. Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: a double-blind, placebo-controlled, randomized phase 2a study. Eur Neuropsychopharmacol. 2025;95:14\u201323. https:\/\/doi.org\/10.1016\/j.euroneuro.2025.03.007.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/s41380-024-02846-5","volume":"30","author":"S Mesens","year":"2025","unstructured":"Mesens S, Kezic I, Van Der Ark P, Etropolski M, Pandina G, Benes H, et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Mol Psychiatry. 2025;30(6):2427\u201335. https:\/\/doi.org\/10.1038\/s41380-024-02846-5.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1245_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","volume":"9","author":"K Recourt","year":"2019","unstructured":"Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019;9(1):216. https:\/\/doi.org\/10.1038\/s41398-019-0553-z.","journal-title":"Transl Psychiatry"},{"key":"1245_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.70158","author":"L Palagini","year":"2025","unstructured":"Palagini L, Alfi G, Aquino G, Grenno G, Anastasio L, Annuzzi E, et al. Emotion regulation and executive functions in insomnia disorder comorbid with mood and sedative-hypnotic use disorders: findings from a naturalistic longitudinal study employing daridorexant in the management of chronic insomnia. J Sleep Res. 2025. https:\/\/doi.org\/10.1111\/jsr.70158.","journal-title":"J Sleep Res"},{"issue":"6","key":"1245_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14196","volume":"33","author":"L Palagini","year":"2024","unstructured":"Palagini L, Alfi G, Gurrieri R, Annuzzi E, Caruso V, Gambini M, et al. Early experience with the new DORA daridorexant in patients with insomnia disorder and comorbid mental disturbances: results of a naturalistic study with 3 months follow-up. J Sleep Res. 2024;33(6):e14196. https:\/\/doi.org\/10.1111\/jsr.14196.","journal-title":"J Sleep Res"},{"key":"1245_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020. https:\/\/doi.org\/10.1093\/sleep\/zsaa123.","journal-title":"Sleep"},{"issue":"12","key":"1245_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254.","journal-title":"JAMA Netw Open"},{"key":"1245_CR21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","edition":"5"},{"key":"1245_CR22","unstructured":"Dayvigo\u00ae Tablets, Interview Form. 2024 [cited 2025; Available from: https:\/\/image.packageinsert.jp\/pdf.php?mode=1&yjcode=1190027F1022]. Accessed 8 May 2025."},{"key":"1245_CR23","volume-title":"Insomnia: psychological assessment and management","author":"C Morin","year":"1993","unstructured":"Morin C. Insomnia: psychological assessment and management. Guilford Press; 1993."},{"issue":"4","key":"1245_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s1389-9457(00)00065-4","volume":"2","author":"CH Bastien","year":"2001","unstructured":"Bastien CH, Valli\u00e8res A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297\u2013307. https:\/\/doi.org\/10.1016\/s1389-9457(00)00065-4.","journal-title":"Sleep Med"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.11477\/mf.1405200864","volume":"24","author":"T Munezawa","year":"2009","unstructured":"Munezawa T. Development of the Japanese version of the Insomnia Severity Index (ISI-J). Jpn J Psychiatr Treat. 2009;24:219\u201325. https:\/\/doi.org\/10.11477\/mf.1405200864.","journal-title":"Jpn J Psychiatr Treat"},{"issue":"1","key":"1245_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362. https:\/\/doi.org\/10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1245_CR27","doi-asserted-by":"publisher","DOI":"10.1037\/e591322011-001","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Education, and Welfare, Public Health Service, US Department of Health; 1976. https:\/\/doi.org\/10.1037\/e591322011-001."},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u201335. https:\/\/doi.org\/10.1192\/bjp.133.5.429.","journal-title":"Br J Psychiatry"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/NSS.S499090","volume":"17","author":"CL Drake","year":"2025","unstructured":"Drake CL, Yardley J, Pinner K, Moline M, Malhotra M. Perception of lemborexant effectiveness as assessed by the patient global impression-insomnia questionnaire. Nat Sci Sleep. 2025;17:557\u201370. https:\/\/doi.org\/10.2147\/NSS.S499090.","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"1245_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/sleep\/31.1.79","volume":"31","author":"AD Krystal","year":"2008","unstructured":"Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79\u201390. https:\/\/doi.org\/10.1093\/sleep\/31.1.79.","journal-title":"Sleep"},{"issue":"1\u20132","key":"1245_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jad.2007.06.011","volume":"106","author":"M Berk","year":"2008","unstructured":"Berk M, Ng F, Wang WV, Calabrese JR, Mitchell PB, Malhi GS, et al. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord. 2008;106(1\u20132):153\u20138. https:\/\/doi.org\/10.1016\/j.jad.2007.06.011.","journal-title":"J Affect Disord"},{"issue":"1","key":"1245_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03087-4","volume":"14","author":"T Kishi","year":"2024","unstructured":"Kishi T, Koebis M, Sugawara M, Kawatsu Y, Taninaga T, Iwata N. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. Transl Psychiatry. 2024;14(1):374. https:\/\/doi.org\/10.1038\/s41398-024-03087-4.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"1245_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013;150(2):384\u20138. https:\/\/doi.org\/10.1016\/j.jad.2013.04.028.","journal-title":"J Affect Disord"},{"issue":"6","key":"1245_CR34","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3122\/jabfm.2013.06.130064","volume":"26","author":"C Gagnon","year":"2013","unstructured":"Gagnon C, B\u00e9langer L, Ivers H, Morin CM. Validation of the insomnia severity index in primary care. J Am Board Fam Med. 2013;26(6):701\u201310. https:\/\/doi.org\/10.3122\/jabfm.2013.06.130064.","journal-title":"J Am Board Fam Med"},{"issue":"1","key":"1245_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3108-3","volume":"20","author":"L Clifton","year":"2019","unstructured":"Clifton L, Clifton DA. The correlation between baseline score and post-intervention score, and its implications for statistical analysis. Trials. 2019;20(1):43. https:\/\/doi.org\/10.1186\/s13063-018-3108-3.","journal-title":"Trials"},{"issue":"10","key":"1245_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.5664\/jcsm.5094","volume":"11","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Kamijo A, Nagai R. Patient background factors affecting the therapeutic outcomes in response to eszopiclone in adult patients with chronic insomnia: a post hoc analysis of a double-blind phase III study in Japan. J Clin Sleep Med. 2015;11(10):1171\u20138. https:\/\/doi.org\/10.5664\/jcsm.5094.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"1245_CR37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4088\/jcp.v69n0807","volume":"69","author":"WS Gilmer","year":"2008","unstructured":"Gilmer WS, Gollan JK, Wisniewski SR, Howland RH, Trivedi MH, Miyahara S, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry. 2008;69(8):1246\u201356. https:\/\/doi.org\/10.4088\/jcp.v69n0807.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1245_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-016-0060-6","volume":"4","author":"K Joyce","year":"2016","unstructured":"Joyce K, Thompson A, Marwaha S. Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review. Int J Bipolar Disord. 2016;4(1):19. https:\/\/doi.org\/10.1186\/s40345-016-0060-6.","journal-title":"Int J Bipolar Disord"},{"key":"1245_CR39","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2147\/NDT.S305331","volume":"17","author":"AJ Rush","year":"2021","unstructured":"Rush AJ, South C, Jain S, Agha R, Zhang M, Shrestha S, et al. Clinically significant changes in the 17- and 6-Item Hamilton Rating Scales for depression: a STAR*D report. Neuropsychiatr Dis Treat. 2021;17:2333\u201345. https:\/\/doi.org\/10.2147\/NDT.S305331.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1245_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104532","volume":"134","author":"MM Zhang","year":"2022","unstructured":"Zhang MM, Ma Y, Du LT, Wang K, Li Z, Zhu W, et al. Sleep disorders and non-sleep circadian disorders predict depression: a systematic review and meta-analysis of longitudinal studies. Neurosci Biobehav Rev. 2022;134:104532. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104532.","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"1245_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz122","volume":"42","author":"X Ji","year":"2019","unstructured":"Ji X, Ivers H, Savard J, LeBlanc M, Morin CM. Residual symptoms after natural remission of insomnia: associations with relapse over 4 years. Sleep. 2019;42(8):zsz122. https:\/\/doi.org\/10.1093\/sleep\/zsz122.","journal-title":"Sleep"},{"issue":"Suppl 1","key":"1245_CR42","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1093\/geroni\/igz038.1340","volume":"3","author":"M Liu","year":"2019","unstructured":"Liu M, Szanton SL, Vitiello MV. Bidirectional associations between sleep complaints and depression: findings from the NHATS study. Innov Aging. 2019;3(Suppl 1):S367. https:\/\/doi.org\/10.1093\/geroni\/igz038.1340.","journal-title":"Innov Aging"},{"issue":"12","key":"1245_CR43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/sleep\/33.12.1693","volume":"33","author":"E Yokoyama","year":"2010","unstructured":"Yokoyama E, Kaneita Y, Saito Y, Uchiyama M, Matsuzaki Y, Tamaki T, et al. Association between depression and insomnia subtypes: a longitudinal study on the elderly in Japan. Sleep. 2010;33(12):1693\u2013702. https:\/\/doi.org\/10.1093\/sleep\/33.12.1693.","journal-title":"Sleep"},{"issue":"5","key":"1245_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz288","volume":"43","author":"TF Blanken","year":"2020","unstructured":"Blanken TF, Borsboom D, Penninx BW, Van Someren EJ. Network outcome analysis identifies difficulty initiating sleep as a primary target for prevention of depression: a 6-year prospective study. Sleep. 2020;43(5):zsz288. https:\/\/doi.org\/10.1093\/sleep\/zsz288.","journal-title":"Sleep"},{"issue":"4","key":"1245_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/npr2.12205","volume":"41","author":"T Kishi","year":"2021","unstructured":"Kishi T, Nishida M, Koebis M, Taninaga T, Muramoto K, Kubota N, et al. Evidence-based insomnia treatment strategy using novel orexin antagonists: a review. Neuropsychopharmacol Rep. 2021;41(4):450\u20138. https:\/\/doi.org\/10.1002\/npr2.12205.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"4","key":"1245_CR46","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1007\/s12325-024-02811-2","volume":"41","author":"M Ozone","year":"2024","unstructured":"Ozone M, Hirota S, Ariyoshi Y, Hayashida K, Ikegami A, Habukawa M, et al. Efficacy and safety of transitioning to lemborexant from z-drug, suvorexant, and ramelteon in Japanese insomnia patients: an open-label, multicenter study. Adv Ther. 2024;41(4):1728\u201345. https:\/\/doi.org\/10.1007\/s12325-024-02811-2.","journal-title":"Adv Ther"},{"issue":"2","key":"1245_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40268-024-00462-w","volume":"24","author":"K Mishima","year":"2024","unstructured":"Mishima K, Fujimoto K, Endo A, Ishii M. Safety and efficacy of lemborexant in insomnia patients: results of a postmarketing observational study of Dayvigo\u00ae tablets. Drugs R D. 2024;24(2):211\u201326. https:\/\/doi.org\/10.1007\/s40268-024-00462-w.","journal-title":"Drugs R D"},{"issue":"4","key":"1245_CR48","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00406-024-01891-z","volume":"275","author":"M Schredl","year":"2025","unstructured":"Schredl M, Anzenberger E, Schilling C. Nightmare frequency and nightmare distress in psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci. 2025;275(4):1189\u201395. https:\/\/doi.org\/10.1007\/s00406-024-01891-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01245-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:08:51Z","timestamp":1771430931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01245-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01245-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.Taka. has received lecture fees from Eisai, Takeda Pharmaceutical, Sumitomo Pharma, Otsuka Pharmaceutical, Mochida Pharmaceutical, Lundbeck Japan, Viatris Pharmaceuticals Japan, Nobelpharma, Meiji Seika Pharma, MSD, Daiichi Sankyo, and Shionogi & Co. outside the submitted work. H.M. has received honoraria from Eisai, Otsuka Pharmaceutical, Mochida Pharmaceutical, Sumitomo Pharma, Takeda Pharmaceutical, Kyowa Kirin, MSD, Meiji Seika Pharma, Janssen Pharmaceutical, Yoshitomi Pharmaceutical Industries, and Viatris Pharmaceuticals Japan. M.T. has received honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Daiichi Sankyo, Sumitomo Pharma, Meiji Seika Pharma, Viatris Pharmaceuticals, MSD, Eisai, and Yoshitomi Pharmaceutical. M.Ka. has received consulting fees from Sumitomo Pharma, Otsuka Pharmaceutical, Lundbeck Japan, and Shionogi & Co. and honoraria from Sumitomo Pharma, Eisai, Janssen Pharmaceutical, Meiji Seika Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Viatris, Mitsubishi Tanabe Pharma, MSD, Eli Lilly, Shionogi & Co., Lundbeck Japan, Kyowa Pharmaceutical, and Ono Pharmaceutical. H.Hi. received all support for the present manuscript from Eisai. H.Ho. received all support for the present manuscript from Eisai, and received honoraria from Sumitomo Pharma, Eisai, Janssen Pharmaceutical, Meiji Seika Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Viatris. K.I. received all support for the present manuscript from Eisai, and honoraria from Eisai, MSD, Otsuka Pharmaceutical, Kyowa Kirin, Kowa Pharmaceutical, Shionogi & Co., Sumitomo Pharma, Daiichi Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Boehringer Ingelheim Japan, Novartis Pharma, Pfizer Japan, Meiji Seika Pharma, Mochida Pharmaceutical, Janssen Pharmaceutical, Lundbeck Japan, Yoshitomi Pharmaceutical Industries, Ono Pharmaceutical, Nipro, Nexera Pharma, EA Pharma, and Viatris Pharmaceuticals Japan. H.S. has received grants from Japan Society for the Promotion of Science, Japan Research Foundation Clinical Pharmacology, and Takeda Science Foundation, and honorarium from Viatris, Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomi Pharmaceutical Industries, Sumitomo Pharma, Kyowa Pharmaceutical, MSD, Mochida Pharmaceutical, and Lundbeck Japan. M.O. has received grants from Mitsubishi Tanabe Pharma, Tsumura, Shionogi & Co., Mochida Pharmaceutical, Sumitomo Pharma, Otsuka Pharmaceutical, Kyowa Kirin, Teijin Pharma and honoraria from Eisai, Tsumura, MSD, Meiji Seika Pharma, Takeda Pharmaceutical, Nobel pharma, Taisho Pharmaceutical, Daiichi Sankyo, and Shionogi & Co. Y.Ko. received all support for the present manuscript from Eisai; grants from JSPS KAKENHI; consulting fees from Takeda Pharmaceutical; and honoraria from Takeda Pharmaceutical, Lundbeck Japan, Sumitomo Pharma, Otsuka Pharmaceutical, and Sanwa Kagaku Kenkyusho. T.M. has received honoraria from Sumitomo Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Viatris, and Shionogi & Co. T.T. has received lecture fees from Sumitomo Pharma, Daiichi Sankyo, Viatris, Eisai, Mochida Pharmaceutical, and Shionogi & Co. K.W. received all support for the present manuscript; received grants from Eisai, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, and Takeda Pharmaceutical; consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Viatris; honoraria from Boehringer Ingelheim, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Viatris; and has participated on DSMB or advisory board of Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Nippon Chemiphar, and Otsuka Pharmaceutical. H.Y. received all support for the present manuscript from Eisai. M.Ko. and Y.Ka. are full-time employees of Eisai Co., Ltd. Y.Take. has received grant funding from the Japan Society for the Promotion of Science and speaker\u2019s honoraria from Eisai, Meiji Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Lundbeck, Daiichi Sankyo, Takeda Pharmaceutical, UCB Japan, Novartis, Teijin Pharma, Nippon Boehringer Ingelheim, and Mitsubishi Tanabe Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol, protocol amendments, and all study-related documents were reviewed and approved by the review board of the University of the Ryukyus for clinical research (approval no.: 19-2). Study registration number is jRCTs071220037. The study was conducted in accordance with the protocol, and complied with the Clinical Trials Act, the Declaration of Helsinki, and all local laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The dataset generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material"}},{"value":"No custom code or scripts were developed specifically for this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design of the study: Y.Taka., T.T., K.W., and M.Ko. Data collection and investigation: Y.Taka., H.M., M.T., M.Ka., H.Hi., H.Ho., K.I., H.S., M.O., Y.Ko., T.M., T.T., K.W., H.Y., and Y.Take. Project management: Y.Taka., M.Ko., and Y.Ka. Writing and revising of the original draft: Y.Taka., M.Ko., and Y.Ka. Writing review and editing: Y.Taka., H.M., M.T., M.Ka., H.Hi., H.Ho., K.I., H.S., M.O., Y.Ko., T.M., T.T., K.W., H.Y., M.Ko., Y.Ka., and Y.Take. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}